CURR Pengajuan SEC - CURRENC Group Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1643301

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CURRENC Group Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

April 1, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe
March 4, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2025 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Em
January 10, 2025	EX-1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
December 26, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2024 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Em
December 26, 2024	EX-10.2	AVENIR WELLNESS SOLUTIONS, INC., F/K/A CURE PHARMACEUTICAL HOLDING CORP. SENIOR SECURED NOTE EXHIBIT 10.2 PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED BECAUSE IT IS NOT MATERIAL AND OF A TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH REDACTED PORTIONS ARE INDICATED WITH “[***].” THE ISSUANCE AND SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERR
December 26, 2024	EX-10.1	SETTLEMENT AGREEMENT WITH MUTUAL RELEASES EX-10.1 2 avrwex101.htm SETTLEMENT AGREEMENT WITH MUTUAL RELEASES EXHIBIT 10.1 SETTLEMENT AGREEMENT WITH MUTUAL RELEASES This Settlement Agreement (“Agreement”), made effective this 15th day of December, 2024 (“Effective Date”), is by and between Avenir Wellness Solutions, Inc., f/k/a Cure Pharmaceutical Holding Corp. (“Avenir” or the “Company”), a Delaware corporation maintaining its principal pl
November 19, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55908 AVENIR WELLNESS SOLU
November 15, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING NT 10-Q 1 avrwnt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report o
October 9, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-59908 AVENI
October 9, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-59908 AVEN
October 9, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-59908
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55908 AVENIR WELLNESS SOLUTIONS
July 5, 2024	EX-10.2	Form of Note dated as of June 28, 2024, issued by the Company to the investor. EXHIBIT 10.2 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINIO
July 5, 2024	EX-10.1	Securities Purchase Agreement dated as of June 28, 2024, by and between the Company and the investor. EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of June 28, 2024, by and between AVENIR WELLNESS SOLUTIONS, INC., a Delaware corporation, with its address at 5805 Sepulveda Blvd., Suite 500, Sherman Oaks, California 91411 (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with
July 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Employ
May 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55908 AVENIR WELLNESS SOLUTION
May 17, 2024	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries Avenir Wellness Solutions of California, Inc. (f/k/a CURE Pharmaceutical Corporation), a California corporation The Sera Labs, Inc., a Delaware corporation
May 17, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number333-204857 AVENIR WELLNESS
May 17, 2024	EX-10.37	Distribution Services Agreement, dated April 1, 2022, by and between The Sera Labs, Inc. and Advanced Legacy Technologies LLC EXHIBIT 10.37 This Distribution Services Agreement (“Agreement”) is entered into as of April 1, 2022 (“Effective Date”) by and between The Sera Labs, Inc. (“TSL” or “Sera Labs”) located at 5805 Sepulveda Blvd., #801, Sherman Oaks California, 91411, and Advanced Legacy Technologies LLC (“ALT”), located at 5805 Sepulveda Blvd., #801, Sherman Oaks, CA 91411. RECITALS WHEREAS, services include, but ar
May 16, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio
May 7, 2024	8-K/A	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Employ
May 2, 2024	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Employer
April 25, 2024	CORRESP	5805 Sepulveda Blvd, Suite 801 · Sherman Oaks, CA · 91411 · 424.273.8675 5805 Sepulveda Blvd, Suite 801 · Sherman Oaks, CA · 91411 · 424.273.8675 April 25, 2024 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Washington, DC 20549 Re: Avenir Wellness Solutions, Inc. Form 10-K for the Year Ended December 31, 2022 Form 10-Q for the Period Ended September 30, 2023 Dear Ladies and Gentlemen: We are in receipt of your
April 1, 2024	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe
March 29, 2024	CORRESP	5805 Sepulveda Blvd, Suite 801 · Sherman Oaks, CA · 91411 · 424.273.8675 5805 Sepulveda Blvd, Suite 801 · Sherman Oaks, CA · 91411 · 424.273.8675 March 29, 2024 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Washington, DC 20549 Re: Avenir Wellness Solutions, Inc. Form 10-K for the Year Ended December 31, 2022 Form 10-Q for the Period Ended September 30, 2023 Dear Ladies and Gentlemen: We are in receipt of your
February 20, 2024	CORRESP	5805 Sepulveda Blvd, Suite 801 · Sherman Oaks, CA · 91411 · 424.273.8675 5805 Sepulveda Blvd, Suite 801 · Sherman Oaks, CA · 91411 · 424.273.8675 February 16, 2024 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Washington, DC 20549 Re: Avenir Wellness Solutions, Inc. Form 10-K for the Year Ended December 31, 2022 Form 10-Q for the Period Ended September 30, 2023 Dear Ladies and Gentlemen: We are in receipt of yo
January 12, 2024	EX-10.1	Senior Secured Promissory and Security Agreement dated as of January 4, 2024, by and between the Company and the Executive EXHIBIT 10.1 AVENIR WELLNESS SOLUTIONS, INC. SENIOR SECURED PROMISSORY NOTE AND SECURITY AGREEMENT Up to $250,000 Sherman Oaks, California January 4, 2024 FOR VALUE RECEIVED, AVENIR WELLNESS SOLUTIONS, INC., a Delaware corporation (the “Company”), promises to pay to the order of NANCY DUITCH (the “Holder”) the principal amount of $250,000 (the “Principal Amount”) consisting of: (i) the initial pri
January 12, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Empl
November 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55908 AVENIR WELLNESS SOLU
September 19, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):September 14, 2023 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Em
September 19, 2023	EX-99.1	AVENIR WELLNESS SOLUTIONS ANNOUNCES RETURN OF STOCK TRADING BACK TO OTCQB MARKET EXHIBIT 99.1 AVENIR WELLNESS SOLUTIONS ANNOUNCES RETURN OF STOCK TRADING BACK TO OTCQB MARKET SHERMAN OAKS, CA-–(ACCESSWIRE)–-September 19, 2023 – Avenir Wellness Solutions, Inc. (OTCQB: AVRW) (“Avenir” or the “Company”), a proprietary broad platform technology and wellness company, announced today that the trading of its common stock has been moved back to the OTC Market Group Inc.’s (the “OTC Ma
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55908 AVENIR WELLNESS SOLUTIONS
August 11, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2023 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Emplo
August 11, 2023	EX-99.1	Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity New Branding Reflects Company’s Commitment to the Future of Wellness EXHIBIT 99.1 Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity New Branding Reflects Company’s Commitment to the Future of Wellness SHERMAN OAKS, CA-(ACCESSWIRE)-August 8, 2023 – Avenir Wellness Solutions, Inc. (OTC Pink: CURR) (“Avenir” or the “Company”), a proprietary broad platform and wellness technology company, today announced that it has rece
July 28, 2023	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries Avenir Wellness Solutions of California, LLC (f/k/a CURE Pharmaceutical Corporation), a California corporation The Sera Labs, Inc., a Delaware corporation
July 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 AVENIR WELLNES
July 28, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 AVENIR WELLNESS SOLUTIO
May 22, 2023	EX-99.1	Avenir Wellness Solutions Update to Stockholders Company’s stock trading moved from OTCQB to OTC Pink Market for late filing of 2022 Annual Report due to auditor change – Company to re-apply to OTCQB when filings made current Pre-sales and initial sa EXHIBIT 99.1 Avenir Wellness Solutions Update to Stockholders Company’s stock trading moved from OTCQB to OTC Pink Market for late filing of 2022 Annual Report due to auditor change – Company to re-apply to OTCQB when filings made current Pre-sales and initial sales of new transformational product DNA Complex exceeding expectations with extensive coverage of award-winning Actress Nicole Kidman’s u
May 22, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2023 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Employe
May 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio
April 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2023 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Emplo
April 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 90-1504639 (State or other jurisdiction (Commission (IRS Emplo
April 19, 2023	EX-16.1	RBSM LLP letter, dated April 19, 2023 EXHIBIT 16.1 101 Larkspur Landing Circle Suite 321 Larkspur, California 94939 T: 415-448-5061 www.rbsmllp.com April 19, 2023 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: In a letter (via email) dated April 12, 2023, we notified the Audit Committee of the Board of Directors of Avenir Wellness Solutions, Inc., (the “Company”) that we resign and the auditor-client r
March 31, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe
March 8, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 8, 2023 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 37-1765151 (State or other jurisdiction (Commission (IRS Employ
March 8, 2023	EX-10.1	Employment Agreement dated as of January 1, 2023, by and between Avenir Wellness Solutions, Inc. and Nancy Duitch. EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into and made effective as of January 1, 2023 (the “Effective Date”), by and between Avenir Wellness Solutions, Inc. f/k/a CURE Pharmaceutical Holding Corp., a Delaware corporation (the “Company”), and Nancy Duitch, an individual (the “Executive” and, together with the Company, the “Parties” and individually
January 17, 2023	EX-3.1	Certificate of Amendment of Amended and Restated Certificate of Incorporation EXHIBIT 3.1
January 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2022 AVENIR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware 000-55908 37-1765151 (State or other jurisdiction (Commission (IRS Emp
January 17, 2023	EX-99.1	CURE Pharmaceutical Unveils Exciting New Brand Identity with Name Change to Avenir Wellness Solutions, Inc. New branding reflects Company’s commitment to the future of wellness EXHIBIT 99.1 CURE Pharmaceutical Unveils Exciting New Brand Identity with Name Change to Avenir Wellness Solutions, Inc. New branding reflects Company’s commitment to the future of wellness SHERMAN OAKS, CA-(ACCESSWIRE)-January 17, 2023 – CURE Pharmaceutical Holding Corp. (OTCQB: CURR) (“CURE” or the “Company”), a proprietary broad platform and wellness technology company, today announced that it
November 21, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL
November 14, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition P
September 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOLD
August 19, 2022	EX-99.1	CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman EXHIBIT 99.1 CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience.
August 19, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 000-55908 37-1765151 (State or other jurisdiction of incorporation) (
August 16, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 000-55908 NOTIFICATION OF LATE FILING CUSIP NUMBER 23127P104 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transit
July 28, 2022	EX-10.3	Side Letter, dated July 22, 2022, by and between the Company and Buyer. EXHIBIT 10.3 July 22, 2022 TF Tech Ventures, Inc. 4000 N. Federal Highway, Suite 216 Boca Raton, FL 33431 Re: Asset Purchase Ladies and Gentlemen: This letter confirms the agreement (this ?Agreement?), entered into as of July 22, 2022, by and between CURE Pharmaceutical Holding Corp., a Delaware corporation (?Parent?) and TF Tech Ventures, Inc., a Delaware corporation (?Buyer?), in consideration o
July 28, 2022	EX-10.1	Asset Purchase Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer. EXHIBIT 10.1 ASSET PURCHASE AGREEMENT between CURE Pharmaceutical Corporation, and TF Tech Ventures, Inc. dated as of July 22, 2022 Table of Contents Page ARTICLE I PURCHASE AND SALE 2 Section 1.01 Purchase and Sale of Assets 2 Section 1.02 Assumption of Liabilities 2 Section 1.03 Purchase Price 2 Section 1.04 Third-Party Payments 3 Section 1.05 Loan Amount Payoff 3 Section 1.06 Allocation of Purc
July 28, 2022	EX-10.4	Guaranty, dated July 22, 2022, by and between the Company and Buyer. EXHIBIT 10.4 PARENT GUARANTY THIS GUARANTY (?Guaranty?), effective as of July 22, 2022, is made by CURE Pharmaceutical Holding Corp., a Delaware corporation (?Guarantor?), to and for the benefit of TF Tech Ventures, Inc., a Delaware corporation (?Buyer?) and other Buyer Indemnitees (together with Buyer, ?Beneficiaries?, and each of them, a ?Beneficiary?) (each of Guarantor and Beneficiaries, a ?Pa
July 28, 2022	EX-10.7	Employment Agreement, dated July 22, 2022, by and between the Company and Joel Bennett. EXHIBIT 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), effective as of July 22, 2022 (the ?Effective Date?), is made by and between Cure Pharmaceutical Holding Corp., a Delaware corporation (together with its affiliates and any successor thereto, the ?Company?), and Joel Bennett (the ?Executive?) (collectively referred to herein as the ?Parties?). WHEREAS, the Parties mutu
July 28, 2022	EX-10.2	Promissory Note, dated July 22, 2022, issued by Buyer for the benefit of CURE Pharmaceutical. EXHIBIT 10.2 SECURED PROMISSORY NOTE FROM TF TECH VENTURES, INC. $2,000,000 Oxnard, California July 22, 2022 FOR VALUE RECEIVED, TF Tech Ventures, Inc., a Delaware corporation (the ?Borrower?) hereby unconditionally promises to pay to the order of CURE Pharmaceutical Corp. a California corporation (the ?Noteholder?), with its principal address at 5805 Sepulveda Blvd., #801, Van Nuys, CA 91411, the
July 28, 2022	EX-10.5	Transition Services Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer. EXHIBIT 10.5 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?) is made this 22nd day of July, 2022, by and between CURE Pharmaceutical Corporation, a California corporation (?Seller?) and TF Tech Ventures, Inc., a Delaware corporation (?Buyer?). W I T N E S S E T H: WHEREAS, Seller and Buyer are parties to that certain Asset Purchase Agreement, dated as of the dat
July 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 000-55908 37-1765151 (State or other jurisdiction of incorporation) (Co
July 28, 2022	EX-10.6	Trademark License Agreement, dated July 22, 2022, by and between CURE Pharmaceutical and Buyer. EXHIBIT 10.6 TRADEMARK LICENSE AGREEMENT This Trademark License Agreement (?Agreement?) is made and entered into as of July 22, 2022 (the ?Effective Date?) by and between TF Tech Ventures, Inc., a Delaware corporation (?Buyer? or ?Licensor?) and CURE Pharmaceutical Corporation, a California corporation (?Seller?), and CURE Pharmaceutical Holding Corp., a Delaware corporation (?Parent?, together wi
July 28, 2022	EX-99.1	CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology EXHIBIT 99.1 CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million Proceeds Will Be Used to Grow CURE?s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology OXNARD, Calif. ? PR NEWSWIRE ? July 28, 2022 ? CURE Pharmaceutical Holding Corp. (OTC: CURR) (?CURE?), a proprietary platform technology company, today announced that it has s
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOL
April 1, 2022	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries CURE Pharmaceutical Corporation, a California corporation Cure Chemistry Inc., a Delaware corporation The Sera Labs, Inc., a Delaware corporation
April 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEU
April 1, 2022	NT 10-K	SEC FILE NUMBER NT 10-K 1 currnt10k.htm NT 10-K SEC FILE NUMBER 000-55908 CUSIP NUMBER 23127P104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Tran
January 7, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
January 7, 2022	EX-10.1	Forbearance Agreement. EXHIBIT 10.1 FORBEARANCE AGREEMENT This Forbearance Agreement (?Agreement?) is made and entered into this 5th day of January, 2022, by and between, IONIC VENTURES, LLC (?Investor?) and CURE PHARMACEUTICAL HOLDING CORP., a Delaware corporation (?CURE? or the ?Company?) (collectively, the ?Parties?). WHEREAS, the Parties refer herein to the following: (i) that certain Securities Purchase Agreement,
December 3, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOLD
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOL
April 29, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation) (
April 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation) (C
April 6, 2021	EX-99.1	CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 EXHIBIT 99.1 CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 Fiscal Year 2020 Highlights: - Generated dramatic growth in total and pro forma revenue - Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility - Acquired and expanded consumer wellness subsidiary The Sera Labs, Inc. -
March 31, 2021	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries CURE Pharmaceutical Corporation, a California corporation Chemistry Holdings Inc., a Delaware corporation The Sera Labs, Inc., a Delaware corporation
March 31, 2021	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEU
February 25, 2021	EX-99.1	1 EXHIBIT 99.1 CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile Dysfunction Product CUREfilm Blue? OXNARD, Calif.- February 23rd, 2021 -CURE Pharmaceutical Holding Corp. (?CURE? or the ?Company?) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced this week?s st
February 25, 2021	EX-10.1	Consent and Waiver Agreement, dated February 25, 2021, by and between the Registrant and Ionic Ventures, LLC EXHIBIT 10.1 CONSENT AND WAIVER This CONSENT AND WAIVER (this ?Waiver?), dated as of February 25, 2021, is entered into by and between CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the ?Company?), and Ionic Ventures, LLC, a California limited liability company with offices located at 3053 Fillmore Street, Suite 256, S
February 25, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation
February 12, 2021	EX-99.1	CURE Pharmaceutical Announces Promotions and Additions to Board of Directors EXHIBIT 99.1 CURE Pharmaceutical Announces Promotions and Additions to Board of Directors OXNARD, Calif. - February 11, 2021 - CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors. After a dedicated run as
February 12, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
January 6, 2021	EX-99.1	CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue™ EXHIBIT 99.1 CURE Pharmaceutical Receives FDA Approval for its IND Application for Erectile Dysfunction Product CUREfilm Blue™ OXNARD, Calif.- Jan. 5, 2021 - CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S.
January 6, 2021	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
December 15, 2020	EX-99.2	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information and related notes present the historical condensed combined financial information of Cure Pharmaceutical Holding Corp (herein referred to as the “Company”, “we”, “our”, “us”, “CURE” and similar terms unless the context indicates otherwise) and The Sera
December 15, 2020	EX-99.1	THE SERA LABS, INC. TABLE OF CONTENTS EXHIBIT 99.1 THE SERA LABS, INC. TABLE OF CONTENTS CONTENTS PAGE NO. Condensed Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019 2 Unaudited Condensed Statement of Operation for the nine months ended September 30, 2020 3 Unaudited Condensed Statement of Changes in Stockholders’ Deficit for the nine months ended September 30, 2020 4 Unaudited Condensed Statement of Cash Flow
December 15, 2020	8-K/A	Financial Statements and Exhibits - FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation
December 9, 2020	EX-99.1	NICOLE KIDMAN PARTNERS WITH SERALABS A CURE PHARMACEUTICAL COMPANY AS A STRATEGIC BUSINESS PARTNER AND GLOBAL BRAND AMBASSADOR SeraLabs is a Leading CBD Health, Wellness & Beauty Company Kidman’s partnership is exclusively with Sera Labs Topicals EXHIBIT 99.1 NICOLE KIDMAN PARTNERS WITH SERALABS A CURE PHARMACEUTICAL COMPANY AS A STRATEGIC BUSINESS PARTNER AND GLOBAL BRAND AMBASSADOR SeraLabs is a Leading CBD Health, Wellness & Beauty Company Kidman’s partnership is exclusively with Sera Labs Topicals Los Angeles & Oxnard, CA - December 8, 2020 – CURE Pharmaceutical Holdings (OTCQB: CURR) wholly owned subsidiary The Sera Labs, Inc., has en
December 9, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
December 7, 2020	CORRESP	CURE PHARMACEUTICAL HOLDING CORP. 1620 Beacon Place Oxnard, California 93033 CURE PHARMACEUTICAL HOLDING CORP. 1620 Beacon Place Oxnard, California 93033 VIA EDGAR December 7, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, DC 20549 Attn: Mr. Jason L. Drory Re: CURE Pharmaceutical Holding Corp. Registration Statement on Form S-3 File No. 333-251039 Acceleration Request Requested Date: December 9, 2020 Reques
November 30, 2020	S-3	- FORM S-3 As filed with the Securities and Exchange Commission on November 30, 2020 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 37-1765151 (State or other jurisdiction of incorporation or organization) (I.R.S.
November 25, 2020	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on November 25, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 37-1765151 (State or other jurisdiction of incorporation or organiza
November 25, 2020	EX-4.3	Form of Stock Certificate. EXHIBIT 4.3
November 13, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL
November 2, 2020	EX-10.1	Security Purchase Agreement. EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 30, 2020, is by and among CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collective
November 2, 2020	EX-10.5	Secured Promissory Note. EX-10.5 6 currex105.htm SECURED PROMISSORY NOTE EXHIBIT 10.5 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND SUCH STATE SECURITIES LAWS, OR AN EXEMPTION FROM REGISTRATION THEREUNDER, IN EACH CASE, TO THE EXTENT A
November 2, 2020	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
November 2, 2020	EX-10.3	Series B Convertible Note. EXHIBIT 10.3 SERIES B SENIOR SECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A)
November 2, 2020	EX-10.8	Leak-Out Agreement. EXHIBIT 10.8 VStock Transfer, LLC 18 Lafayette Place Woodmere, New York 11598 October 30, 2020 Dear Sirs: This agreement (the “Leak-Out Agreement”) is being delivered to you in connection with that certain understanding by and between CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the “Company”) and the undersigned (“H
November 2, 2020	EX-10.2	Series A Convertible Note. EX-10.2 3 currex102.htm SERIES A CONVERTIBLE NOTE EXHIBIT 10.2 SERIES A SUBORDINATED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, T
November 2, 2020	EX-10.4	Note Purchase Agreement. EXHIBIT 10.4 NOTE PURCHASE AGREEMENT NOTE PURCHASE AGREEMENT (the “Agreement”), dated as of October 30, 2020, by and among CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the “Company”) and the investor signatory hereto (the “Investor”). WHEREAS: A. Concurrently herewith, the Company, the Investor and certain other inve
November 2, 2020	EX-10.6	Master Netting Agreement. EXHIBIT 10.6 MASTER NETTING AGREEMENT MASTER NETTING AGREEMENT (the “Agreement”), dated as of October 30, 2020, by and among CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the “Company”) and the investor signatory hereto (the “Investor”, and together with the Company, the “Parties” and each a “Party”). WHEREAS, prior t
November 2, 2020	EX-10.7	Registration Rights Agreement. EXHIBIT 10.7 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 30, 2020, is by and among CURE Pharmaceutical Holding Corp., a Delaware corporation with offices located at 1620 Beacon Place, Oxnard, California 93033 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the
November 2, 2020	EX-99.1	CURE Pharmaceutical Closes $10 Million Financing - Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline - EXHIBIT 99.1 CURE Pharmaceutical Closes $10 Million Financing - Funds will support the branding & product launch of Cure’s consumer products by newly acquired Sera Labs and the advancement of CURE’s clinical pharmaceutical pipeline - OXNARD, Calif. - November 2, 2020 - CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements
October 29, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
October 22, 2020	8-K	Termination of a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
October 5, 2020	EX-2.1	Agreement and Plan of Merger, dated September 23, 2020, by and between CURE Pharmaceutical Holding Corp. (the “Company”), The Sera Labs, Inc. and the other parties thereto. EX-2.1 2 currex21.htm AGREEMENT AND PLAN OF MERGER EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION BY AND AMONG CURE PHARMACEUTICAL HOLDING CORP., CURE LABS, INC., AND THE SERA LABS, INC. AND NANCY DUITCH, AS THE SECURITYHOLDERS’ REPRESENTATIVE September 23, 2020 ARTICLE 1 – THE MERGER 2 1.1 The Merger 2 1.2 Closing; Effective Time 2 1.3 Effect of the Merger 2 1.4 Closing Deliveries. 2
October 5, 2020	EX-10.1	Form of Lock-Up Agreement. EXHIBIT 10.1 LOCK-UP AGREEMENT October 2, 2020 CURE Pharmaceutical Holding Corp. 1620 Beacon Place Oxnard, California 93033 Ladies and Gentlemen: This Lock-Up Agreement (this “Agreement”) is executed in connection with the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among CURE Pharmaceutical Holding Corp. (the “Acquiror”), CURE Labs, Inc. (“Merger Sub”), and The
October 5, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation)
October 5, 2020	EX-10.2	Employment Agreement, dated October 2, 2020, by and between the Company and Nancy Duitch. EX-10.2 4 currex102.htm EMPLOYMENT AGREEMENT EXHIBIT 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of October 2, 2020 (the “Effective Date”), is made by and between CURE PHARMACEUTICAL HOLDING CORP., a Delaware corporation (together with any successor thereto, the “Company”), and NANCY DUITCH (the “Executive”) (collectively referred to herein as the “Parties”
September 30, 2020	EX-10.1	Secured Promissory Note, dated September 25, 2020, by and between CURE Pharmaceutical Holding Corp. and Ionic Ventures, LLC. EXHIBIT 10.1 THE ISSUANCE AND SALE OF THE SECURITY REPRESENTED BY THIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITY MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (i) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN
September 30, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporatio
September 29, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporatio
September 29, 2020	EX-99.1	CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi- Channel Distribution Platform Company - Acquisition to Support Cash Flow Positive Goal in ~18 Months - EXHIBIT 99.1 CURE Pharmaceutical Completes $20 Million Acquisition of Sera Labs, a Leading Health, Wellness and Beauty Brand Marketing and Multi- Channel Distribution Platform Company - Acquisition to Support Cash Flow Positive Goal in ~18 Months - OXNARD, Calif. -September 24, 2020 - CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The c
September 24, 2020	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporatio
August 14, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOLD
August 14, 2020	EX-10.1	Separation Agreement, dated May 8, 2020, by and between the Company and Jessica Rousset. EXHIBIT 10.1 Cure Pharmaceutical 1620 Beacon Place Oxnard, CA 93033 Phone: 1-805-824-0410 Fax: 1-805-487-7163 May 6, 2020 DELIVERED VIA EMAIL Jessica Rousset 2137 Fargo Street Los Angeles, CA 90039 Re: Separation Agreement Dear Jessica: This Separation Agreement (“Agreement”) confirms the mutual agreement we have reached concerning your separation from employment with CURE Pharmaceutical Corporati
August 7, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
July 28, 2020	EX-99.1	CURE Pharmaceutical to Acquire Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, in a $20 Million Transaction EXHIBIT 99.1 CURE Pharmaceutical to Acquire Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, in a $20 Million Transaction · MOU to acquire 100% of privately held Sera Labs for $20 million, which consists primarily of stock with key earn out considerations totaling up to an additional $20 million within two years of completing the acquisitio
July 28, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation) (C
July 28, 2020	EX-10.1	Secured Promissory Note EXHIBIT 10.1 SECURED PROMISSORY NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS SECURED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT
June 9, 2020	EX-10.1	Release, Waiver and Amendment. EXHIBIT 10.1 RELEASE, WAIVER, AND AMENDMENT This Release, Waiver, and Amendment (this “Amendment”), dated and effective as of June 5, 2020, is between CURE Pharmaceutical Holding Corp., a Delaware corporation (“Acquiror”), and Josh Held, as the Securityholders’ Representative on behalf of the Company Securityholders under the Merger Agreement (“Securityholders’ Representative”). BACKGROUND WHEREAS
June 9, 2020	EX-4.1	Amendment to Warrants to Purchase Common Stock. EX-4.1 2 currex41.htm AMENDMENT TO WARRANTS EXHIBIT 4.1 CURE PHARMACEUTICAL HOLDING CORP. AMENDMENT TO WARRANTS TO PURCHASE COMMON STOCK This Amendment to Warrants to Purchase Common Stock of CURE Pharmaceutical Holding Corp. (this “Amendment”), effective as of June 5, 2020 (the “Amendment Effective Date”), is entered into by and among CURE Pharmaceutical Holding Corp., a Delaware corporation (the
June 9, 2020	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 curr8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdic
May 15, 2020	10-Q	Quarterly Report - FORM 10-Q 10-Q 1 curr10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 333-2
May 15, 2020	10-K/A	Annual Report - FORM 10-K/A 10-K/A 1 curr10ka.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K/ A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm
May 12, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Delaware 333-204857 37-1765151 (State or other jurisdiction of incorporation) (Com
March 30, 2020	EX-4.1	Specimen common stock certificate EXHIBIT 4.1
March 30, 2020	EX-10.17	Form of Restricted Stock Award Agreement for the Amended and Restated 2017 Equity Incentive Plan EXHIBIT 10.17 CURE PHARMACEUTICAL HOLDING CORP. RESTRICTED STOCK AGREEMENT (For U.S. Participants) CURE Pharmaceutical Holding Corp. (the “Company”) has granted to the Participant named in the Notice of Grant of Restricted Stock (the “Grant Notice”) to which this Restricted Stock Agreement (the “Agreement”) is attached an Award consisting of Shares subject to the terms and conditions set forth in
March 30, 2020	10-K	MKKN / Makkanotti Group Corp 10-K - Annual Report - FORM 10-K 10-K 1 curr10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num
March 30, 2020	EX-10.18	Form of Restricted Stock Unit Agreement for the Amended and Restated 2017 Equity Incentive Plan EXHIBIT 10.18 CURE PHARMACEUTICAL HOLDING CORP. RESTRICTED STOCK UNITS AGREEMENT (For U.S. Participants) CURE Pharmaceutical Holding Corp. has granted to the Participant named in the Notice of Grant of Restricted Stock Units (the “Grant Notice”) to which this Restricted Stock Units Agreement (the “Agreement”) is attached an Award consisting of Restricted Stock Units (each a “Unit”) subject to the
March 30, 2020	EX-10.15	Amended and Restated Cure Pharmaceutical Holding Corp. 2017 Equity Incentive Plan EXHIBIT 10.15 AMENDED AND RESTATED CURE PHARMACEUTICAL HOLDING CORP. 2017 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 7 3. Administration 7 3.1 Administration by the Committee 7 3.2 Authority of Officers 7 3.3 Administration with Re
March 30, 2020	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries CURE Pharmaceutical Corporation, a California corporation Chemistry Holdings Inc., a Delaware corporation
March 30, 2020	EX-10.16	Form of Stock Option Agreement for the Amended and Restated 2017 Equity Incentive Plan EXHIBIT 10.16 CURE PHARMACEUTICAL HOLDING CORP. STOCK OPTION AGREEMENT CURE Pharmaceutical Holding Corp. (the “Company”) has granted to the Participant named in the Notice of Grant of Stock Option (the “Grant Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Stock upon the terms and conditions set forth in the
March 30, 2020	EX-4.2	Description of Registrant’s Securities EXHIBIT 4.2 Description of Capital Stock of Cure Pharmaceutical Holding Corp. The following is a description of the capital stock of Cure Pharmaceutical Holding Corp. Our common stock, par value $0.001 per share, is registered under Section 12 of the Securities Exchange Act of 1934, as amended; This description does not describe every aspect of our capital stock and is subject to, and qualified in
January 29, 2020	SC 13G/A	CURR / CURE Pharmaceutical Holding Corp. / Climate Change Investigation, Innovation & Investment Company, Llc - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CURE Pharmaceutical Holding Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23127P104 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des
January 10, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2020 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal
January 10, 2020	EX-99.1	Update on CURE's Investment in Coeptis Pharmaceuticals, Inc EXHIBIT 99.1 Update on CURE's Investment in Coeptis Pharmaceuticals, Inc 10 January 2020 In late 2019, we announced the purchase of a $200,000 convertible promissory note from Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development, and commercialization of branded 505(b)(2) pharmaceutical products. The note represented an initial step toward CURE's poten
December 31, 2019	EX-99.1	CHEMISTRY HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018 AND 2017 TABLE OF CONTENTS EXHIBIT 99.1 CHEMISTRY HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018 AND 2017 TABLE OF CONTENTS Page REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM F-2 CONSOLIDATED FINANCIAL STATEMENTS: Consolidated Balance Sheets F-3 Consolidated Statements of Operations F-4 Consolidated Statements of Changes Stockholders’ Deficit F-5 Consolidated Statements o
December 31, 2019	8-K/A	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment #1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address
December 31, 2019	EX-2.1	Agreement and Plan of Merger and Reorganization, among the Registrant and the parties listed therein, dated March 31, 2019 EXHIBIT 2.1 EXECUTION COPY AGREEMENT AND PLAN OF MERGER AND REORGANIZATION BY AND AMONG CURE PHARMACEUTICAL HOLDING CORP., CURE CHEMISTRY, INC., AND CHEMISTRY HOLDINGS, INC. AND JOSH HELD, AS THE SECURITYHOLDERS’ REPRESENTATIVE March 31, 2019 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 1.1 The Merger 2 1.2 Closing; Effective Time 2 1.3 Effect of the Merger 2 1.4 Closing Deliveries 2 1.5 Certific
December 31, 2019	EX-99.2	UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The unaudited condensed consolidated pro forma statements of operations are presented combining Cure Pharmaceutical Holding Corp’s (“CURE”) condensed audited statement of operations for the year ended December 31, 2018 and Chemistry Holdings Inc.’s (“CHI”) audited condensed statement of operations for the year ended Decem
November 21, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 18, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal
November 21, 2019	EX-99.1	CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors EX-99.1 2 currex991.htm PRESS RELEASE EXHIBIT 99.1 CURE Pharmaceutical Names Canopy Rivers’ Chairman, John K. Bell, To Board of Directors Industry veteran brings 40 years of experience to support CURE’s rapid growth OXNARD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) - CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, F
November 14, 2019	EX-99.1	CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceutical and its Combination Drug for Osteoarthritis Pain and Hypertension EX-99.1 3 currex991.htm PRESS RELEASE EXHIBIT 99.1 Media Inquiries: Paulo Acuna 310.824.9000 [email protected] CURE Pharmaceutical [OTCQB:CURR] Takes First Step to Acquire Coeptis Pharmaceutical and its Combination Drug for Osteoarthritis Pain and Hypertension OXNARD, Calif., November 14, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company
November 14, 2019	EX-10.1	Convertible Promissory Note, between the Registrant and Coeptis Pharmaceuticals, Inc., dated November 12, 2019 EXHIBIT 10.1 CONVERTIBLE PROMISSORY NOTE NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY,
November 14, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal
November 14, 2019	10-Q	CURR / CURE Pharmaceutical Holding Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL
October 4, 2019	EX-3.1	Certificate of Conversion, as filed with the Secretary of State of Delaware on September 30, 2019. EXHIBIT 3.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION of CURE PHARMACEUTICAL HOLDING CORP. (a Nevada Corporation) to CURE PHARMACEUTICAL HOLDING CORP. (a Delaware Corporation) THIS CERTIFICATE OF CONVERSION of Cure Pharmaceutical Holding Corp., a Nevada corporation (the “Nevada Corp.”) to Cure Pharmaceutical Holding Corp., a Delaware Corporation (the “Corporation”) is being executed and filed pu
October 4, 2019	EX-3.2	Amended and Restated Certificate of Incorporation EXHIBIT 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CURE PHARMACEUTICAL HOLDING CORP. a Delaware corporation Cure Pharmaceutical Holding Corp. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), does hereby certify as follows: A. The name of the Corporation is Cure Pharmaceutical
October 4, 2019	EX-3.3	Bylaws of the Registrant. EX-3.3 5 currex33.htm DELAWARE BYLAWS EXHIBIT 3.3 BYLAWS OF CURE PHARMACEUTICAL HOLDING CORP. ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE The registered office of Cure Pharmaceutical Holdings Corp. (the “corporation”) shall be fixed in the corporation’s certificate of incorporation, as the same may be amended from time to time. 1.2 OTHER OFFICES The corporation may at any time establish ot
October 4, 2019	EX-2.1	Plan of Conversion, dated September 27, 2019 EXHIBIT 2.1 PLAN OF CONVERSION OF CURE PHARMACEUTICAL HOLDING, CORP. THIS PLAN OF CONVERSION (this “Plan”) is entered into by Cure Pharmaceutical Holding Corp., Inc., a Nevada corporation (the “Converting Entity”), which intends to convert (the “Conversion”) into Cure Pharmaceutical Holding Corp., Inc., a Delaware corporation (the “Converted Entity”) as of the 27 day of September, 2019. WHEREAS, t
October 4, 2019	EX-3.4	Articles of Conversion, as filed with the Secretary of State of Nevada on September 27, 2019. EXHIBIT 3.4 ARTICLES OF CONVERSION BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Articles of Conversion (PURSUANT TO NRS 92A.205) Page 1 USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY PLEASE NOTE: The charter document for the resulting entity must be submitted/filed simultaneously with t
October 4, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principa
August 14, 2019	10-Q	CURR / CURE Pharmaceutical Holding Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOLD
August 8, 2019	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 curr8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 6, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 9303
July 12, 2019	DEF 14A	CURR / CURE Pharmaceutical Holding Corp. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
July 2, 2019	PRER14A	CURR / CURE Pharmaceutical Holding Corp. PRER14A - - PRER 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defi
July 2, 2019	CORRESP	CURR / CURE Pharmaceutical Holding Corp. CORRESP - - July 2, 2019 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Sergio Chinos Re: Cure Pharmaceutical Holding Corp. Preliminary Proxy Statement on Schedule 14A Filed June 14, 2019 File No. 000-55908 Dear Mr. Chinos: On behalf of our client, Cure Pharmaceutical Holding Corp. (the “Company”), we hereby provide responses to comments (the “Comments”)
June 26, 2019	PRER14A	CURR / CURE Pharmaceutical Holding Corp. PRER14A - - PRER 14A PRER14A 1 currprer14a.htm PRER 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as pe
June 26, 2019	CORRESP	CURR / CURE Pharmaceutical Holding Corp. CORRESP - - June 26, 2019 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Sergio Chinos Re: Cure Pharmaceutical Holding Corp. Preliminary Proxy Statement on Schedule 14A Filed June 14, 2019 File No. 000-55908 Dear Mr. Chinos: On behalf of our client, Cure Pharmaceutical Holding Corp. (the “Company”), we hereby provide responses to comments (the “Comments”
June 14, 2019	PRE 14A	CURR / CURE Pharmaceutical Holding Corp. PRE 14A - - PRE 14A PRE 14A 1 currpre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-
May 20, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 curr8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) Nevada 2834 37-1765151 (State or other juris
May 20, 2019	EX-99.1	CURE Pharmaceutical Expands Leadership Team with Key New Hires EX-99.1 3 currex991.htm PRESS RELEASE EXHIBIT 99.1 Contact: Ashley Ray [email protected] 310.824.9000 (office), 919.630.5508 (cell) CURE Pharmaceutical Expands Leadership Team with Key New Hires Oxnard, Calif. – May 20, 2019 – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of four key hires to their growing leadership team
May 20, 2019	EX-10.1	Employment Agreement between the Registrant and Michael Redard, dated May 15, 2019 EX-10.1 2 currex101.htm EMPLOYMENT AGREEMENT EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of May 15, 2019 (the “Effective Date”), is made by and between CURE Pharmaceutical Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Michael Redard (the “Executive”) (collectively referred to herein as the “Parties”).
May 20, 2019	10-Q	CURR / CURE Pharmaceutical Holding Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOL
May 15, 2019	NT 10-Q	CURR / CURE Pharmaceutical Holding Corp. NT 10-Q NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Fo
May 14, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal exec
May 14, 2019	EX-99.1	CURE Pharmaceutical (OTCQB:CURR) Closes Acquisition Of Privately-Held Chemistry Holdings Inc. Acquired Technology Expands Core CUREfilmTM Platform and Strengthens Balance Sheet EX-99.1 2 currex991.htm PRESS RELEASE EXHIBIT 99.1 Media Inquiries: Ashley Ray 310.824.9000 [email protected] CURE Pharmaceutical (OTCQB:CURR) Closes Acquisition Of Privately-Held Chemistry Holdings Inc. Acquired Technology Expands Core CUREfilmTM Platform and Strengthens Balance Sheet OXNARD, Calif., May 14, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and
May 1, 2019	EX-99.1	CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13 EXHIBIT 99.1 Media Inquiries: Ashley Ray 310.824.9000 [email protected] CURE Pharmaceutical Extends Closing Of Privately-Held Chemistry Holdings Inc. Acquisition to May 13 OXNARD, Calif., May 1, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has extended the close of the previously announced acquisition of Chemi
May 1, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 curr8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 9303
April 12, 2019	RW	CURR / CURE Pharmaceutical Holding Corp. RW FORM RW CURE PHARMACEUTICAL HOLDING CORP. 1620 Beacon Place, Oxnard, California 93033 (805) 824-0410 April 12, 2019 VIA EDGAR U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Cure Pharmaceutical Holding Corp. Request for Withdrawal of Registration Statement on Form S-1 filed on July 9, 2018, as amended on November 30, 2018 File No.: 333-226102 Ladies and Gentl
April 9, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2019 CURE PHARMACEUTICAL HOLDING CORP.
April 1, 2019	EX-99.1	CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery EXHIBIT 99.1 Media Inquiries: Ashley Ray (310) 824-9000 [email protected] CURE Pharmaceutical to Acquire Privately-Held Chemistry Holdings Inc., Expanding Its Technology Platform in Oral Drug Delivery OXNARD, Calif., April 1, 2019 – CURE Pharmaceutical (OTC: CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has agreed to acquire Chemistry Holdings
April 1, 2019	EX-10.1	Convertible Demand Note, between the Registrant and Chemistry Holdings, Inc., dated March 29, 2019 EX-10.1 2 currex101.htm CONVERTIBLE DEMAND NOTE EXHIBIT 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITIES LAW
April 1, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2019 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal ex
April 1, 2019	EX-21.1	List of Subsidiaries of the Registrant EXHIBIT 21.1 List of Subsidiaries CURE Pharmaceutical Corporation, a California corporation Oak Therapeutics, Inc., a majority-owned California corporation
April 1, 2019	10-K	CURR / CURE Pharmaceutical Holding Corp. FORM 10-K (Annual Report) 10-K 1 curr10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num
February 19, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2019 CURE PHARMACEUTICAL HOLDING CORP.
February 15, 2019	SC 13G	CURR / CURE Pharmaceutical Holding Corp. / Hangar202, Llc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CURE PHARMACEUTICAL HOLDING CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 23127P104 (CUSIP Number) c/o Robert Davidson CURE Pharmaceutical Holding Corp. 1620 Beacon Place Oxnard, California 93033 (805) 824-0410 (Name, Address and Tele
January 17, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2019 CURE PHARMACEUTICAL HOLDING CORP.
January 7, 2019	EX-10.2	Advisory Consulting Agreement, between the Registrant and Michael J. Willner, dated December 14, 2018 EXHIBIT 10.2 ADVISORY CONSULTING AGREEMENT This Advisory Board Consulting Agreement (the “Agreement”) is made and effective as of December 14, 2018 (the “Effective Date”), by and between CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”) and Michael J. Willner, an individual (the “Consultant” and together with the Company, the “Parties”). WHEREAS: A. The Consultant entity has
January 7, 2019	EX-10.1	Securities Purchase Agreement, between the Registrant and Michael J. Willner, dated December 14, 2018 EX-10.1 2 currex101.htm SECURITIES PURCHASE AGREEMENT EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 14, 2018, by and between CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”), and Michael J. Willner including, without limitation, the MJW Family Trust (the “Purchaser”). WHEREAS, the Company is offering
January 7, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2018 CURE PHARMACEUTICAL HOLDING CORP.
December 21, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement 8-K 1 curr8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2018 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 333-204857 37-1765151 (State or other jurisdi
December 21, 2018	144	CURR / CURE Pharmaceutical Holding Corp. FORM 144 UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0101 Expires: June 30, 2020 Estimated average burden hours per response............. 1.00 FORM 144 SEC USE ONLY NOTICE OF PROPOSED SALE OF SECURITIES DOCUMENT SEQUENCE NO. PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 CUSIP NUMBER ATTENTION: Transmit for filing 3 copies of this form concur
December 17, 2018	SC 13G	CURR / CURE Pharmaceutical Holding Corp. / Climate Change Investigation, Innovation & Investment Company, Llc - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CURE PHARMACEUTICAL HOLDING CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 23127P104 (CUSIP Number) c/o Robert Davidson CURE Pharmaceutical Holding Corp. 1620 Beacon Place Oxnard, California 93033 (805) 824-0410 (Name, Address and Tele
December 4, 2018	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2018 CURE PHARMACEUTICAL HOLDING CORP.
November 30, 2018	EX-10.5	Employment Agreement dated March 15 , 201 7 with Jessica Rousset+ EXHIBIT 10.5 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), effective as of March 15, 2017 (the “Effective Date”), is made by and between CURE Pharmaceutical Corporation, a Delaware corporation (together with any successor thereto, the “Company”), and Jessica Rousset (the “Executive”) (collectively referred to herein as the “Parties”). WHEREAS, the Parties mutually desire to se
November 30, 2018	S-1/A	CURR / CURE Pharmaceutical Holding Corp. FORM S-1/A As filed with the Securities and Exchange Commission on November 30, 2018 Registration No.
November 30, 2018	EX-14.1	Code of Ethics of the Company+ EX-14.1 3 currex141.htm CODE OF ETHICS EXHIBIT 14.1 CURE PHARMACEUTICAL HOLDING CORP. CODE OF ETHICS INTRODUCTION This Code of Ethics (this "Code") is applicable to the (1) Chairman of the Board and/or Chief Executive Officer, (2) Chief Scientific Officer and/or President, (2) Chief Operating Officer, (3) Chief Financial Officer or Treasurer or Secretary, (4) Chief Business Officer, and (5) other
November 23, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2018 CURE PHARMACEUTICAL HOLDING CORP.
November 20, 2018	EX-10.1	Employment Agreement, between the Registrant and Alex Katz, dated November 15, 2018 EXHIBIT 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made effective as of November 15, 2018 (the “Effective Date”) between Alex Katz (“Employee”) and CURE Pharmaceutical Holding Corp., hereinafter referred to as (“CURE” or the “Company”), who are hereinafter sometimes collectively referred to as “the parties” or singularly as a “party.” WITNESSETH WHEREAS, CURE wishes t
November 20, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2018 CURE PHARMACEUTICAL HOLDING CORP.
November 14, 2018	10-Q	CURR / CURE Pharmaceutical Holding Corp. FORM 10-Q (Quarterly Report) 10-Q 1 curr10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 3
October 17, 2018	EX-10.1	Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 15, 2018, among CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”), and [*] (the “Purchaser”). WHEREAS, the Company is offering a Note to acquire up to that number of shares of Common Stock as is determined in accordance with the terms of the Note; WHEREAS, s
October 17, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 15, 2018 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal
October 11, 2018	EX-99.1	CURE Pharmaceutical Holding Corp.’s 2017 Equity Incentive Plan. EX-99.1 4 currex991.htm 2017 EQUITY INCENTIVE PLAN EXHIBIT 99.1 CURE PHARMACEUTICAL HOLDING CORP. 2017 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 9 3.1 Administration by the Committee 9 3.2 Authority of Officers
October 11, 2018	S-8	CURR / CURE Pharmaceutical Holding Corp. FORM S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 37-1765151 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification Number) 1620 Beacon Place, Oxnard, Califor
October 5, 2018	RW	CURR / CURE Pharmaceutical Holding Corp. RW FORM RW CURE PHARMACEUTICAL HOLDING CORP. 1620 Beacon Place Oxnard, California 93033 (805) 824-0410 October 5, 2018 VIA EDGAR U.S. Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Cure Pharmaceutical Holding Corp. Application for Withdrawal of Registration Statement on FORM S-8 (File No.: 333-222565) SEC Accession No. 0001477932-18-000250 Filed: January 16, 2018 De
September 5, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2018 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) 1620 Beacon Place, Oxnard, California 93033 (Address of principal
September 5, 2018	EX-99.1	CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world EXHIBIT 99.1 Media Inquiries: Ashley Ray (310) 824 – 9000 [email protected] CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world LOS ANGELES – September 5, 2018 - CURE Pharmaceutical (OTC: CURR), (“CURE”), an innovative drug delivery and devel
August 20, 2018	10-Q	CURR / CURE Pharmaceutical Holding Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOLD
August 15, 2018	NT 10-Q	CURR / CURE Pharmaceutical Holding Corp. NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-204857 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: June 30, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing i
July 9, 2018	EX-14.1	Code of Ethics (incorporated by reference to our Registration Statement on Form S-1 filed on July 9, 2018) EXHIBIT 14.1 CURE PHARMACEUTICAL HOLDING CORP. CODE OF ETHICS INTRODUCTION This Code of Ethics (this "Code") is applicable to the (1) Chairman of the Board and/or Chief Executive Officer, (2) Chief Scientific Officer and/or President, (2) Chief Operating Officer, (3) Chief Financial Officer or Treasurer or Secretary, (4) Chief Business Officer, and (5) other persons performing similar functions (c
July 9, 2018	S-1	CURR / CURE Pharmaceutical Holding Corp. FORM S-1 As filed with the Securities and Exchange Commission on July 9, 2018 Registration No.
May 15, 2018	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 ¨ Transition Report pursuant to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 ? Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOL
March 26, 2018	EX-10.5.1	Form of 9% Convertible Note EXHIBIT 10.5.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFE
March 26, 2018	EX-10.5.2	Form of Common Stock Purchase Warrant EX-10.5.2 4 currex1052.htm FORM OF WARRANT EXHIBIT 10.5.2 EXHIBIT B NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND APPLICABLE STATE SECURITI
March 26, 2018	10-K	CURR / CURE Pharmaceutical Holding Corp. FORM 10-K (Annual Report) 10-K 1 curr10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2017 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 333-204857 37-1765151 (State or Other Jurisdiction of Incorpora
March 26, 2018	EX-10.5	Form of Securities Purchase Agreement EX-10.5 2 currex105.htm FORM OF SECURITIES PURCHASE AGREEMENT EXHIBIT 10.5 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February , 2018, among CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collect
March 1, 2018	8-A12G	CURR / CURE Pharmaceutical Holding Corp. FORM 8-A12G curr8a12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT 1934 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 37-1765151 (State or other jurisdiction of incorporation or organization) (IRS Employer Id
January 25, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers curr8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2018 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) Nevada 2834 37-1765151 (State or other jurisdiction of
January 16, 2018	S-8	CURR / CURE Pharmaceutical Holding Corp. FORM S-8 currs8.htm Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 37-1765151 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification Number) 1620 Beacon Place, Oxna
January 16, 2018	EX-99.1	CURE Pharmaceutical Holding Corp.’s 2017 Equity Incentive Plan. currex991.htm EXHIBIT 99.1 CURE PHARMACEUTICAL HOLDING CORP. 2017 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 9 3.1 Administration by the Committee 9 3.2 Authority of Officers 9 3.3 Administration with Respect to
December 29, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2017 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of small business issuer as specified in its charter) Nevada 2834 37-1765151 (State or other jurisdiction of incorporat
December 13, 2017	DEF 14A	CURR / CURE Pharmaceutical Holding Corp. DEF 14A currdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) x Definiti
November 14, 2017	10-Q	CURR / CURE Pharmaceutical Holding Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2017 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICA
October 30, 2017	CORRESP	CURR / CURE Pharmaceutical Holding Corp. ESP currcorresp.htm October 27, 2017 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Attn: Terence O?Brien Re: Cure Pharmaceutical Holding Corp Form 10-K for Fiscal Year Ended December 31, 2016, Filed April 17, 2017 Form 10-Q as of June 30, 2017, Filed on August 14, 2017 File No. 333-204857 Dear Mr. O?Brien: Please find below responses to certain
August 14, 2017	10-Q	CURR / CURE Pharmaceutical Holding Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOLD
May 15, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 ¨ Transition Report pursuant to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 CURE PHARMACEUTICAL HOL
April 17, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2016 CURE PHARMACEUTICAL HOLDING CORP. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2016 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 333-204857 37-1765151 (State or Other Jurisdiction of Incorporation) (Commission File Number
March 31, 2017	NT 10-K	Makkanotti Group NT 10-K NT 10-K 1 currnt10k.htm NT 10-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number 333-204857 NOTIFICATION OF LATE FILING x Form 10-K ¨ Form 11-K ¨ Form 20-F ¨ Form 10-Q ¨ Form N-SAR For Period Ended: December 31, 2016 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For th
December 14, 2016	8-K/A	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K/A 1 mkkn8ka.htm FORM 8-KA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment #1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):November 7, 2016 CURE PHARMACEUTICAL HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 333-204857 37-1765151 (S
December 14, 2016	EX-10.4	Form of Warrant to Purchase Common Stock EX-10.4 3 mkknex104.htm FORM OF WARRANT EXHIBIT 10.4 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED
December 14, 2016	EX-99.3	UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS mkknex993.htm EXHIBIT 99.3 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The unaudited condensed consolidated pro forma statements of operations are presented combining Cure Pharmaceutical Corporation?s (?Cure?) condensed audited statement of operations for the year ended December 31, 2015 and Cure Pharmaceutical Holding Corp?s (?the Company? or ?CPHC?) audited condensed statemen
December 14, 2016	EX-99.2	FINANCIAL STATEMENTS Cure Pharmaceutical Corporation mkknex992.htm EXHIBIT 99.2 FINANCIAL STATEMENTS Cure Pharmaceutical Corporation Condensed Balance Sheets (unaudited) F-2 Condensed Statements of Operations (unaudited) F-3 Condensed Statements of Cash Flows (unaudited) F-4 Notes to Condensed Financial Statements (unaudited) F-5 F-1 Cure Pharmaceutical Corporation Condensed Balance Sheets September 30, 2016 December 31, 2015 (unaudited) Assets Curr
December 14, 2016	EX-3.4	Certificate of Amendment to Articles of Incorporation (incorporated by reference to the Form 8-K, as filed with the Securities and Exchange Commission on December 14, 2016) EX-3.4 2 mkknex34.htm CERTIFICATE OF AMENDMENT EXHIBIT 3.4 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Web site: www.nvsos.gov Filed in the office of Barbara K. Cegayske Secretary of State State of Nevada Document Number 20160518990-91 Filing Date and Time 11/30/2016 8:53 AM Entity Number E0258352014-1 Certificate of Amendment (PURSU
November 15, 2016	EX-99.1	FINANCIAL STATEMENTS Cure Pharmaceutical Corporation EXHIBIT 99.1 FINANCIAL STATEMENTS Cure Pharmaceutical Corporation Report of Independent Registered Public Accounting Firm F-2 Balance Sheets F-3 Statements of Operations F-4 Statement of Stockholders’ Deficit F-5 Statements of Cash Flows F-6 Notes to Financial Statements F-7 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of CURE Pharmaceutica
November 15, 2016	EX-10.2	Form of Share Cancellation Agreement EXHIBIT 10.2 FORM OF SHARE CANCELLATION AGREEMENT This SHARE CANCELLATION AGREEMENT (this “Agreement”), dated November 7, 2016 (the “Effective Date”), is entered into by and among (the “Company”), Makkanotti Group Corp., a Nevada corporation, (the “Company”), [ · ] (the “Cancelling Party”). The Company and Cancelling Party are also hereinafter individually and jointly referred to as “P(p)arty” and
November 15, 2016	EX-99.3	UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS EXHIBIT 99.3 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The unaudited condensed consolidated pro forma statements of operations are presented combining Cure Pharmaceutical Corporation?s (?Cure?) condensed audited statement of operations for the year ended December 31, 2015 and Makkanotti Group Corp?s (?the Company? or ?Makkanotti?) audited condensed statement of operations for
November 15, 2016	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2016 (November 7, 201 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2016 (November 7, 2016) MAKKANOTTI GROUP CORP. (Exact name of registrant as specified in its charter) Nevada 333-204857 37-1765151 (State or other jurisdiction of incorpor
November 15, 2016	EX-3.3	Amendment to the Bylaws (incorporated by reference from the registrant’s Current Report on Form 8-K filed on November 15, 2016) EXHIBIT 3.3 AMENDMENTS TO THE BYLAWS OF MAKKANOTTI GROUP CORP. 1. Subsections .01, .02, .03 and .07 of Section I of the Bylaws of Makkanotti Group Corp. (the “Corporation”) shall each be amended and restated in their entirety as follows: “.01 Annual Meetings. The annual meeting of the shareholders of this Corporation, for the purpose of election of Directors and for such other business as may prop
November 15, 2016	EX-21.1	List of Subsidiaries of the Registrant (incorporated by reference to the Form 8-K, as filed with the Securities and Exchange Commission on November 15, 2016). EXHIBIT 21.1 SUBSIDIARIES Cure Pharmaceutical Corporation, a California corporation
November 15, 2016	EX-2.1	Share Exchange and Conversion Agreement, among the Registrant and the parties listed therein, dated November 8, 2016 EXHIBIT 2.1 SHARE EXCHANGE AND CONVERSION AGREEMENT by and among MAKKANOTTI GROUP CORP. (“PUBCO”), a Nevada corporation and THE MAJORITY STOCKHOLDER OF PUBCO on the one hand; and CURE PHARMACEUTICAL CORPORATION (“PRIVECO”), a California corporation and THE STOCKHOLDERS OF PRIVECO and THE NOTEHOLDERS OF PRIVECO on the other hand Dated as of November 7, 2016 1 SHARE EXCHANGE AND CONVERSION AGREEMENT
November 15, 2016	EX-10.3	Form of Warrant to Purchase Common Stock EXHIBIT 10.3 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
November 15, 2016	EX-99.2	FINANCIAL STATEMENTS Cure Pharmaceutical Corporation EXHIBIT 99.2 FINANCIAL STATEMENTS Cure Pharmaceutical Corporation Condensed Balance Sheets (unaudited) F-2 Condensed Statements of Operations (unaudited) F-3 Condensed Statements of Cash Flows (unaudited) F-4 Notes to Condensed Financial Statements (unaudited) F-5 F-1 Cure Pharmaceutical Corporation Condensed Balance Sheets June 30, 2016 December 31, 2015 (unaudited) Assets Current assets: Cash $
November 7, 2016	10-Q	Makkanotti Group FORM 10-Q (Quarterly Report) 10-Q 1 mkkn10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 3
August 25, 2016	EX-10.1	Agreement for Sale of Assets, dated June 28, 2016 mkkn101.htm EXHIBIT 10.1 AGREEMENT FOR SALE OF ASSETS This AGREEMENT FOR SALE OF ASSETS (this "Agreement") is made on August 19, 2016 between Makkanotti Group Corp., a Nevada corporation (the "Company") and Anna Ionnou (such individual, the "Founder"). WHEREAS, the Founder, as holder of the majority of the Company's outstanding common stock, entered into a Stock Purchase Agreement (the "Stock Purc
August 25, 2016	8-K	Makkanotti FORM 8-K (Current Report/Significant Event) mkkn8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 19, 2016 Makkanotti Group Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 333-204857 37-1765151 (State of incorporation) (Commission File Number)
August 15, 2016	10-Q	Makkanotti FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 Makkanotti Group Corp. (
August 15, 2016	10-Q	Makkanotti FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 ¨ Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 Makkanotti Group Corp. (
July 22, 2016	8-K	Changes in Registrant's Certifying Accountant mkkn8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 19, 2016 Makkanotti Group Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 333-204857 37-1765151 (State of incorporation) (Commission File Number) (
July 22, 2016	EX-16.1	Letter from Paritz & Co., P.A. mkknex161.htm EXHIBIT 16.1 Paritz & Company, P.A Certified Public Accountants 15 Warren Street, Suite 25 Hackensack, New Jersey 07601 (201) 342-7753 Fax: (201) 342-7598 July 22, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K of Makkanotti Group Corp. dated July 22, 2016. We agree with the statements made conc
July 1, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers mkkn8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2016 Makkanotti Group Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 333-204857 37-1765151 (State of incorporation) (Commission File Number) (
June 24, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March 31, 2016 [ ] Transition Report pursuant to Sect UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended March 31, 2016 [ ] Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 Makkanotti Group Corp. (Exa
March 11, 2016	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Amendment 2 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Amendment 2 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 Makk
March 3, 2016	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Amendment 1 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Amendment 1 [X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 [ ] Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 333-204857 Makk

CURR / CURRENC Group Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)